Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-07-05
2011-07-05
Schultz, James (Doug) (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S006120, C514S04400A
Reexamination Certificate
active
07973156
ABSTRACT:
According to the present invention, purified, isolated and cloned nucleic acid polynucleotide encoding hypoxia-regulating genes and the proteins thereof and antibodies directed against the proteins which have sequences as set forth in SEQ ID No:1, SEQ ID No:2, SEQ ID No:3, SEQ ID No:4, SEQ ID No:5 and SEQ ID No:6 are provided. The present invention further provides transgenic animals and cell lines as well as knock-out organisms of these sequences. The present invention further provides methods of regulating angiogenesis or apoptosis or regulating response to hypoxic conditions in a patient in need of such treatment. The present invention also provides a method of diagnosing the presence of ischemia in a patient including the steps of analyzing a bodily fluid or tissue sample from the patient for the presence or gene product of at least one expressed gene (up-regulated) as set forth in the group comprising SEQ ID No:2; SEQ ID No:3; SEQ ID No:4; SEQ ID No:5; and SEQ ID No:6 and where ischemia is determined if the up-regulated gene or gene product is ascertained.
REFERENCES:
patent: 3791993 (1974-02-01), Schuurs et al.
patent: 3839153 (1974-10-01), Schuurs et al.
patent: 3850572 (1974-11-01), Andrus
patent: 3850578 (1974-11-01), McConnell
patent: 3853987 (1974-12-01), Dreyer
patent: 3867517 (1975-02-01), Ling
patent: 3879262 (1975-04-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4666828 (1987-05-01), Gusella
patent: 4683202 (1987-07-01), Mullis
patent: 4736866 (1988-04-01), Leder et al.
patent: 4801531 (1989-01-01), Frossard
patent: 4866042 (1989-09-01), Neuwelt
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4879219 (1989-11-01), Wands et al.
patent: 5011771 (1991-04-01), Bellet et al.
patent: 5175383 (1992-12-01), Leder et al.
patent: 5175384 (1992-12-01), Krimpenfort et al.
patent: 5175385 (1992-12-01), Wagner et al.
patent: 5192659 (1993-03-01), Simons
patent: 5221778 (1993-06-01), Byrne et al.
patent: 5225347 (1993-07-01), Goldberg et al.
patent: 5272057 (1993-12-01), Smulson
patent: 5281521 (1994-01-01), Trojanowski et al.
patent: 5288846 (1994-02-01), Quertermous et al.
patent: 5298422 (1994-03-01), Schwartz et al.
patent: 5347075 (1994-09-01), Sorge
patent: 5360735 (1994-11-01), Weinshank et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5487992 (1996-01-01), Capecchi et al.
patent: 5614396 (1997-03-01), Bradley et al.
patent: 5807743 (1998-09-01), Stinchcomb et al.
patent: 5846721 (1998-12-01), Soares et al.
patent: 5877021 (1999-03-01), Stinchcomb et al.
patent: 5912326 (1999-06-01), Chang
patent: 6194150 (2001-02-01), Stinchcomb et al.
patent: 6300132 (2001-10-01), Monia
patent: 6346398 (2002-02-01), Pavco et al.
patent: 6350934 (2002-02-01), Zwick et al.
patent: 6410518 (2002-06-01), Monia
patent: 6455674 (2002-09-01), Einat et al.
patent: 6555667 (2003-04-01), Einat et al.
patent: 6617438 (2003-09-01), Matulic-Adamic et al.
patent: 6656731 (2003-12-01), Eckstein et al.
patent: 6682930 (2004-01-01), Lu
patent: 6740738 (2004-05-01), Einat et al.
patent: 6818447 (2004-11-01), Pavco et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0104973 (2003-06-01), Einat et al.
patent: 1009753 (2005-04-01), None
patent: 06303997 (1994-11-01), None
patent: 406303997 (1994-11-01), None
patent: WO 93/14200 (1993-07-01), None
patent: WO 94/06908 (1994-03-01), None
patent: WO 94/23049 (1994-10-01), None
patent: WO 94/28123 (1994-12-01), None
patent: WO 96/39426 (1996-12-01), None
patent: WO 98/05352 (1998-02-01), None
patent: WO 99/09049 (1999-02-01), None
Vickers et al. J. Biol. Chem (2003) 276(9) 7106-7118.
Agrawal S., “Antisense oligonucleotides: towards clinical trials”,Trends Biotechnol.14(10):376-387 (1996).
Agrawal et al, “Antisense therapeutics: is it as simple as complementary base recognition?”Mol. Med. Today61:72-81 (2000).
Akhter et al, “Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)”,Nuc. Res., 19:5551-5559 (1991).
Alon et al., “Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity”,Nat. Med.1(10):1024-1028 (1995).
Attwood T, “The Babel of Bioinformatics”,Science290:471-473 (2000).
Benjamin et al., “Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal”,Proc. Natl. Acad. Sci. USA94:(16):8761-8766 (1997).
Berendsen H, “A Glimpse of the Holy Grail?”,Science282:642-643 (1998).
Blaesse, “Gene Therapy for Cancer”,Sci. Am.276(6):111-115 (1997).
Bouck et al., “How tumors become angiogenic”Adv. Cancer Res.69:135-174 (1996).
Branch, “A good antisense molecule is hard to find”,TIBS23:45-50 (1998).
Bunn et al., “Oxygen sensing and molecular adaption in hypoxia”,Physiol. Rev.76:839-885 (1996).
Burke et al., “Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors,”Methods in Enzymology, vol. 194, “Guide to Yeast genetics and Molecular Biology”, eds. Guthrie et al., Academic Press, Inc. Chap. 17, pp. 251-270 (1991).
Calabretta et al., “Antisense strategies in the treatment of leukemias”,Semin. Oncol., 23:78 (1996).
Capecchi, “Altering the genome by homologous recombination”,Science244:1288-1292 (1989).
Carmeliet et al., “Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis”,Nature394(66923):485-490 (1998).
Crooke, “Progress in antisense therapeutics”, (1995)Hematol. Pathol., 2:29 (1995).
Davies et al., “Targeted alterations in yeast artificial chromosomes for inter-species gene transfer”,Nucleic Acids Research20(11):2693-2698 (1992).
Dickinson et al., “High frequency gene targeting using insertional vectors”,Human Molecular Genetics2(8):1299-2302 (1993).
Duff et al., “Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human APP gene and expression in ES cells”,Research Advances in Alzheimer's Disease and Related Disorders(1995).
Duke et al., “Cell Suicide in Health and Disease”,Sci. Am., pp. 80-87 (1996).
Eckstein, “Nucleotide Phosphorothioates”,Ann. Rev. Biochem.54:367-402 (1985).
Feigner, “Nonviral Strategies for Gene Therapy”,Sci. Am.pp. 102-106 (1997).
Fitch “Homology: a personal view on some of the problems”,TIG16(5):227-231 (2000).
Fyodorov et al., “et-1, a novel ETS domain factor that can activate neuronal nAchR gene transcription”,J. Neurobiol., 34(2):151-163 (1998).
Gallagher et al., “Identification of p53 Genetic Suppressor Elements which Confer Resistance to Cisplatin”,Oncogene14:185-193 (1997).
Galperin et al., “Who's your neighbor? New computational approaches for functional genomics”,Nature Biotech.18:609-613 (2000).
Gerwitz, “Oligodeoxynucleotide-based therapeutics for human leukemias”,Stem Cells Dayt.11:96 (1993).
Gerwitz et al., “Facilitating oligonucleotide delivery: helping antisense deliver on its promise”,Proc. Natl. Acad. Sci.93:3161-3163 (1996).
Gordon, “Transgenic Animals”,Intl. Rev. Cytol.115:171-229 (1989).
Hanahan et al., “Patterns and Emerging Mechanisms of Angiogenic Switch During Tumorigenesis”Cell86:353-364 (1996).
Hanania et al., “Recent advances in the application of gene therapy to human disease”,Am. J. Med.99:537 (1995).
Herskowitz, “Functional Inactivation of Genes by Dominant Negative Mutations,”Nature329 (6136) :219-222 (1987).
Holzmayer et
Einat Paz
Luria Sylvie
Skaliter Rami
Cooper & Dunham LLP
Quark Pharmaceuticals Inc.
Schultz James (Doug)
White John P.
LandOfFree
Hypoxia-regulated genes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hypoxia-regulated genes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hypoxia-regulated genes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679371